Lipoprotein-associated phospholipase A2: A new biomarker for cardiovascular risk assessment and potential therapeutic target

Expert Review of Molecular Diagnostics

Volumn 7, Issue 5, 2007, Pages 511-517

  Carlquist, John F ^a   Muhlestein, Joseph B ^b   Anderson, Jeffrey L ^b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Coronary disease; Lipoprotein associated phospholipase A 2; Lp PLA2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; AZETIDINONE DERIVATIVE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOKINE; DARAPLADIB; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINIC ACID; PHOSPHOLIPASE A2; POLYUNSATURATED FATTY ACID; PRAVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; FATTY ACID; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; HUMAN; HYDROLYSIS; ISCHEMIC HEART DISEASE; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATION; PATIENT ASSESSMENT; PATIENT CARE; PATIENT SAFETY; SCREENING TEST; STROKE; SYSTEMATIC REVIEW; UPREGULATION; BLOOD; DIFFERENTIAL DIAGNOSIS; REVIEW; RISK ASSESSMENT;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; FATTY ACIDS, NONESTERIFIED; HUMANS; RISK ASSESSMENT;

EID: 35148858377     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.5.511     Document Type: Article

References (38)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62(5), 707-714 (1977).
2. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J. Biol. Chem. 262, 4223-4230 (1987).
3. Tew DG, Southan C, Rice SQ et al. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 16(4), 591-599 (1996).
4. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69, 419-445 (2000).
5. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit. Care Med. 30(Suppl. 5), S294-S301 (2002).
6. Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim. Biophys. Acta 1761(11), 1359-1372 (2006).
7. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am. J. Respir. Crit. Care Med. 162(2 Pt 1), 523-527 (2000).
8. Opal S, Laterre PF, Abraham E et al. Controlled mortality trial of platelet-activating factor acetylhydrolase in severe sepsis investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. 32(2), 332-341 (2004).
9. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem. J. 338(Pt 2), 479-487 (1999).
10. 2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 115(21), 2715-2721(2007).
11. Stafforini DM, Numao T, Tsodikov A et al. Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. Clin. Invest. 103(7), 989-997 (1999).
12. 2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J. Clin. Endocrinol. Metab. 91(9), 3521-3527 (2006).
13. 2 activity is a marker of small, dense LDL particles in human plasma. Clin. Chem. 51(12), 2264-2273 (2005).
14. 2 was found to approximately elevate low-density lipoprotein in discriminating coronary disease cases and controls.
15. 2 and atherosclerosis.
16. 2 as a risk marker drawing subjects from a large randomized trial. The seminal report generating interest in this biomarker.
17. 2 and prognosis after myocardial infarction in the community. Arterioscler. Thromb. Vasc. Biol. 26(11), 2517-2522 (2006).
18. 2 levels and the risk of future cardiovascular events in women. J. Am. Coll. Cardiol. 38(5), 1302-1306 (2001).
19. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350(14), 1387-1397 (2004). •• Large study calling for re-evaluation of the use of C-reactive protein (CRP) as a predictor of coronary disease.
20. 2 and cardiovascular disease: a systematic review. Mayo Clin. Proc. 82(2), 159-165 (2007).
21. The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. Am. J. Epidemiol. 129(4), 687-702 (1989).
22. 2 and CRP to the traditional risk model for atherosclerosis. These markers do not substantially improve existing models.
23. 2 is especially predictive of coronary artery disease among patients with the metabolic syndrome. J. Am. Coll. Cardiol. 49(9), A339 (2007).
24. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276(11), 875-881 (1996).
25. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109(7), 837-842 (2004).
26. 2 levels. Atherosclerosis 182(1), 193-198 (2005).
27. 2 in patients with coronary heart disease versus control subjects. Am. J. Cardiol. 95(9), 1025-1032 (2005).
28. 2 in obese patients with metabolic syndrome. Atherosclerosis (2007) (Epub ahead of print).
29. 2 as a therapeutically successful metric.
30. Kuvin JT, Dave DM, Sliney KA et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol. 98(6), 743-745 (2006).
31. 2 mass and activity with calcified coronary plaque in young adults: the CARDIA Study. Aterioscler. Thromb. Vasc. Biol. 25(1), 216-221 (2005).
32. 2 for coronary artery disease death and all-cause mortality as assayed by mass versus activity J. Am. Coll. Cardiol. 49(9), A329 (2007)
33. 2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation 113(14), 1745-1752 (2006).
34. 2. Clin. Lab. Med. 3, 679-697 (2006).
35. 2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch. Intern. Med. 165(21), 2479-2484 (2005).
36. 2, and outcome after ischemic stroke. Arch. Intern. Med. 166(19), 2073-2080 (2006).
37. Varsan VS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113, 2335-2362 (2006).
38. Anderson JL, Carlquist JF, Horne BD, Hopkins PN. Progress in unraveling the genetics of coronary artery disease and myocardial infarction. Curr. Atherosclerosis Reports 9, 179-186 (2007).